Literature DB >> 17914064

Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

A S Chen-Plotkin1, W Yuan, C Anderson, E McCarty Wood, H I Hurtig, C M Clark, B L Miller, V M-Y Lee, J Q Trojanowski, M Grossman, V M Van Deerlin.   

Abstract

BACKGROUND: Mutations in the LRRK2 gene are an important cause of familial and nonfamilial parkinsonism. Despite pleomorphic pathology, LRRK2 mutations are believed to manifest clinically as typical Parkinson disease (PD). However, most genetic screens have been limited to PD clinic populations.
OBJECTIVE: To clinically characterize LRRK2 mutations in cases recruited from a spectrum of neurodegenerative diseases.
METHODS: We screened for the common G2019S mutation and several additional previously reported LRRK2 mutations in 434 individuals. A total of 254 patients recruited from neurodegenerative disease clinics and 180 neurodegenerative disease autopsy cases from the University of Pennsylvania brain bank were evaluated.
RESULTS: Eight cases were found to harbor a LRRK2 mutation. Among patients with a mutation, two presented with cognitive deficits leading to clinical diagnoses of corticobasal syndrome and primary progressive aphasia.
CONCLUSION: The clinical presentation of LRRK2-associated neurodegenerative disease may be more heterogeneous than previously assumed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914064      PMCID: PMC3619720          DOI: 10.1212/01.WNL.0000280574.17166.26

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.

Authors:  Daniela Berg; Katherine J Schweitzer; Petra Leitner; Alexander Zimprich; Peter Lichtner; Petra Belcredi; Theresa Brüssel; Claudia Schulte; Sylvia Maass; Thomas Nägele; Zbigniew K Wszolek; Thomas Gasser
Journal:  Brain       Date:  2005-12       Impact factor: 13.501

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Biochemical and pathological characterization of Lrrk2.

Authors:  Benoit I Giasson; Jason P Covy; Nancy M Bonini; Howard I Hurtig; Matthew J Farrer; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

4.  LRRK2 mutations are not common in Alzheimer's disease.

Authors:  Mathias Toft; Sigrid Botne Sando; Stacey Melquist; Owen A Ross; Linda R White; Jan O Aasly; Matthew J Farrer
Journal:  Mech Ageing Dev       Date:  2005-11       Impact factor: 5.432

5.  Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy.

Authors:  Adam L Boxer; Michael D Geschwind; Nataliya Belfor; Maria Luisa Gorno-Tempini; Guido F Schauer; Bruce L Miller; Michael W Weiner; Howard J Rosen
Journal:  Arch Neurol       Date:  2006-01

6.  Lrrk2 R1441 substitution and progressive supranuclear palsy.

Authors:  O A Ross; A J Whittle; S A Cobb; M M Hulihan; S J Lincoln; M Toft; M J Farrer; D W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2006-02       Impact factor: 8.090

7.  Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Authors:  Justus C Dächsel; Owen A Ross; Ignacio F Mata; Jennifer Kachergus; Mathias Toft; Ashley Cannon; Matt Baker; Jennifer Adamson; Mike Hutton; Dennis W Dickson; Matthew J Farrer
Journal:  Acta Neuropathol       Date:  2006-12-07       Impact factor: 17.088

8.  Corticodentatonigral degeneration with neuronal achromasia.

Authors:  J J Rebeiz; E H Kolodny; E P Richardson
Journal:  Arch Neurol       Date:  1968-01

9.  Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations.

Authors:  Vivianna M Van Deerlin; Elisabeth McCarty Wood; Peachie Moore; Wuxing Yuan; Mark S Forman; Christopher M Clark; Manuela Neumann; Linda K Kwong; John Q Trojanowski; Virginia M-Y Lee; Murray Grossman
Journal:  Arch Neurol       Date:  2007-08

10.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

View more
  24 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

2.  Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Authors:  Monica Sanchez-Contreras; Michael G Heckman; Pawel Tacik; Nancy Diehl; Patricia H Brown; Alexandra I Soto-Ortolaza; Elizabeth A Christopher; Ronald L Walton; Owen A Ross; Lawrence I Golbe; Neill Graff-Radford; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers
Journal:  Mov Disord       Date:  2016-10-06       Impact factor: 10.338

3.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

4.  How does the genetic assassin select its neuronal target?

Authors:  James C Stevens; Elizabeth M C Fisher; Simon Mead
Journal:  Mamm Genome       Date:  2011-03-04       Impact factor: 2.957

5.  Neurodegenerative disease: can synucleinopathy and tauopathy be identified during life?

Authors:  Shin-ichiro Kubo; Nobutaka Hattori
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

6.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

Review 7.  Parkinson's disease: Exit toxins, enter genetics.

Authors:  Marie Westerlund; Barry Hoffer; Lars Olson
Journal:  Prog Neurobiol       Date:  2009-11-17       Impact factor: 11.685

8.  A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.

Authors:  Shinsuke Fujioka; Bradley F Boeve; Joseph E Parisi; Pawel Tacik; Naoya Aoki; Audrey J Strongosky; Matt Baker; Monica Sanchez-Contreras; Owen A Ross; Rosa Rademakers; Vesna Sossi; Dennis W Dickson; A Jon Stoessl; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-08-19       Impact factor: 4.891

9.  Exome sequencing in familial corticobasal degeneration.

Authors:  Robert Fekete; Matthew Bainbridge; Jose Fidel Baizabal-Carvallo; Andreana Rivera; Bradley Miller; Peicheng Du; Vladyslav Kholodovych; Suzanne Powell; William Ondo
Journal:  Parkinsonism Relat Disord       Date:  2013-07-16       Impact factor: 4.891

10.  Ancient origin of the Parkinson disease gene LRRK2.

Authors:  Ignacio Marín
Journal:  J Mol Evol       Date:  2008-06-04       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.